Atara biotherapeutics reports inducement grants under nasdaq listing rule 5635(c)(4)

Thousand oaks, calif.--( business wire )--atara biotherapeutics, inc. (nasdaq: atra), a leader in t-cell immunotherapy, leveraging its novel allogeneic epstein-barr virus (ebv) t-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of 36,750 restricted stock units of atara's common stock to three newly hired employees and stock options to purchase an aggregate of 48,300 shares of atara's common stock to two such newly hired employees. these awards were approved by the compensation committee of atara's board of directors and granted under the atara biotherapeutics, inc. 2018 inducement plan, with a grant date of february 1, 2023, as an inducement material to the new employee entering into employment with atara, in accordance with nasdaq listing rule 5635(c)(4).
ATRA Ratings Summary
ATRA Quant Ranking